DNB Asset Management Boosts DexCom Stake by 271.8%

Institutional investor now owns over 1 million shares of medical device company

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

DNB Asset Management AS, a Norwegian investment firm, has significantly increased its stake in DexCom, Inc. (NASDAQ:DXCM), a leading medical device company that develops continuous glucose monitoring (CGM) systems. According to a recent SEC filing, DNB Asset Management raised its holdings in DexCom by 271.8% during the third quarter, now owning 1,098,544 shares worth approximately $73.9 million.

Why it matters

DexCom's CGM systems are an important tool for diabetes management, and the company has seen strong growth as adoption of the technology has increased. DNB Asset Management's substantial investment in the company suggests the firm sees significant long-term potential in DexCom's business and technology.

The details

DNB Asset Management acquired an additional 803,086 shares of DexCom during the third quarter, bringing its total ownership to over 1 million shares. This represents about 0.28% of DexCom's outstanding stock. The investment firm cited DexCom's leading position in the CGM market and the company's strong financial performance as reasons for the increased stake.

  • DNB Asset Management filed the SEC report detailing the stake increase on February 27, 2026.
  • The firm acquired the additional 803,086 shares during the third quarter of 2025.

The players

DNB Asset Management AS

A Norwegian investment management firm that oversees over $100 billion in assets.

DexCom, Inc.

A medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

DNB Asset Management's substantial investment in DexCom underscores the growing importance of CGM technology in diabetes management and the firm's confidence in DexCom's market leadership and long-term growth potential.